Previous 10 | Next 10 |
REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the companyȁ...
Sierra Oncology ( SRRA +7.2% ) announces long-term safety and dose intensity data on momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, in more than 550 myelofibrosis patients. The results were presented at EHA. More news on: Sierra Oncology, Inc., Healthcare stocks news, Stocks on the mov...
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib Canada NewsWire VANCOUVER, BC, June 12, 2020 - Data presented at the 25 th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and...
- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28 th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June 3 rd - VANCOUVER , May 27, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development com...
Sierra Oncology (NASDAQ: SRRA ) appoints Dr. Stephen Dilly as President and Chief Executive Officer (CEO), effective June 1, 2020. More news on: Sierra Oncology, Inc., Healthcare stocks news, Read more ...
- Mr. Craig Collard appointed to the Board of Directors - VANCOUVER , May 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potent...
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress Canada NewsWire VANCOUVER, May 14, 2020 - Momelotinib's demonstrable anemia benefit and low myelosuppressive potential...
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis Canada NewsWire VANCOUVER, May 7, 20...
Sierra Oncology (NASDAQ: SRRA ): Q1 Non-GAAP EPS of -$1.31; GAAP EPS of -$3.14 misses by $0.40 . More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications highlighting durability, safety, and efficacy data for momelotinib planned throughout 2020 ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...